Baird Financial Group, Inc. Akebia Therapeutics, Inc. Transaction History
Baird Financial Group, Inc.
- $50.2 Billion
- Q3 2024
A detailed history of Baird Financial Group, Inc. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 17,393 shares of AKBA stock, worth $32,003. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,393
Previous 17,393
-0.0%
Holding current value
$32,003
Previous $17,000
29.41%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding AKBA
# of Institutions
120Shares Held
54.8MCall Options Held
291KPut Options Held
179K-
Black Rock Inc. New York, NY11.6MShares$21.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$18.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$10.6 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$8.75 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$6.84 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $338M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...